Literature DB >> 2253201

Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.

E J Wawrzynczak1, A J Cumber, R V Henry, J May, D R Newell, G D Parnell, N R Worrell, J A Forrester.   

Abstract

A panel of immunotoxins was constructed by chemically attaching the ribosome-inactivating proteins abrin A chain, ricin A chain, gelonin, and momordin to the monoclonal mouse IgG2a antibody Fib75 by means of a disulfide linkage. All the immunotoxins were toxic in tissue culture to the EJ human bladder carcinoma cell line expressing the antigen recognized by Fib75, inhibiting the incorporation of [3H]leucine by 50% at concentrations between 1 x 10(-10) M and 8 x 10(-10) M. The pharmacokinetics of the immunotoxins in the normal Wistar rat was determined following i.v. administration. The concentrations of intact immunotoxin in serum samples taken at various intervals after injection for up to 24 h were measured by solid-phase enzyme-linked immunosorbent assays specific for each of the four different ribosome-inactivating proteins. The Fib75 immunotoxins were cleared from the circulation with comparable, but not identical, biphasic kinetics best described by a two compartment open pharmacokinetic model. The alpha-phase half-lives of the panel, between 0.35 and 0.71 h, were similar. The beta-phase half-life of Fib75-abrin A chain, 13.3 h, was significantly longer than the beta-phase half-lives of Fib75-ricin A chain, Fib75-gelonin, and Fib75-momordin, between 7.5 and 8.6 h. Fib75-abrin A chain was found to be about 3- to 4-fold more resistant than the other immunotoxins to breakdown by reduction of the disulfide linkage between the A chain and the antibody with glutathione in vitro. This suggests that the longer serum half-life of Fib75-abrin A chain may have been due to greater stability against reduction in vivo. Analysis of serum samples obtained up to 24 h after injection of Fib75-abrin A chain revealed that the chemically intact immunotoxin present in the circulation retained full cytotoxic activity. An abrin A chain immunotoxin made with a different monoclonal mouse IgG2a antibody was also found to be more stable against reduction by glutathione in vitro than an analogous ricin A chain immunotoxin. Thus, abrin A chain may posses unique molecular properties that endow immunotoxins made with this A chain with greater stability in vivo than immunotoxins made with ricin A chain or other ribosome-inactivating proteins.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253201

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Inhibition of protein synthesis leading to unfolded protein response is the major event in abrin-mediated apoptosis.

Authors:  Ritu Mishra; Meenakshi Sundaram Kumar; Anjali A Karande
Journal:  Mol Cell Biochem       Date:  2015-03-10       Impact factor: 3.396

2.  Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates.

Authors:  D M Fishwild; H M Wu; S F Carroll; S L Bernhard
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

3.  Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.

Authors:  K Mujoo; L Cheung; J L Murray; M G Rosenblum
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

Review 4.  Systemic immunotoxin therapy of cancer: advances and prospects.

Authors:  E J Wawrzynczak
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

Review 5.  Chinese Herbal Medicine-induced Liver Injury.

Authors:  Xin Ma; Jing-Hua Peng; Yi-Yang Hu
Journal:  J Clin Transl Hepatol       Date:  2014-09-15

Review 6.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

7.  Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immunotoxin.

Authors:  J A Calvete; D R Newell; C J Charlton; A F Wright
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

8.  Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer.

Authors:  E J Wawrzynczak; U Zangemeister-Wittke; R Waibel; R V Henry; G D Parnell; A J Cumber; M Jones; R A Stahel
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

9.  Endoplasmic reticulum stress-mediated activation of p38 MAPK, Caspase-2 and Caspase-8 leads to abrin-induced apoptosis.

Authors:  Ritu Mishra; Anjali A Karande
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.